NSTEMI Risk Prediction with the Combination of the Biomarkers Epicardial Adipose Tissue and Soluble Suppression of Tumorigenicity 2

Jiayu Yin; Bowen Qiu; Tingting Li; Yifei Tao; Xiaosong Gu

doi:10.12659/MSM.947019

10 March 2025 : Clinical Research

NSTEMI Risk Prediction with the Combination of the Biomarkers Epicardial Adipose Tissue and Soluble Suppression of Tumorigenicity 2

Jiayu Yin^{ACEFG 1}, Bowen Qiu^{BCEF 2}, Tingting Li^{CE 1}, Yifei Tao^{ADE 3*}, Xiaosong Gu^{AG 1}

DOI: 10.12659/MSM.947019

Med Sci Monit 2025; 31:e947019

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 1 Flow diagram of the study cohort. NSTEMI – non-ST-elevation myocardial infarction; PCI – percutaneous coronary intervention; CTA – completed computed tomography angiography; MACEs – major adverse cardiac events; sST2 – soluble suppression of tumorigenicity 2. This figure was generated using Microsoft PowerPoint, Microsoft, Redmond, WA, USA.

Back to the Article

NSTEMI Risk Prediction with the Combination of the Biomarkers Epicardial Adipose Tissue and Soluble Suppression of Tumorigenicity 2

Your Privacy